Dr Reddy's shares surged after Nomura maintained bullish call with a 2.5% target upgrade, citing biosimilar pipeline catalysts

Mon 28 Sep 2026

Heard on Live television at 12:52:35 IST.

• Nomura maintained buy call on Dr Reddy's with 2.5% target upgrade.
• Key trigger cited: US FDA biological facility clearance and Aflibercept biosimilar decision due December 18, 2026.
• Drug used to treat inflammation; management optimistic on positive regulatory outcome, calling it a potential game changer.
• Company planning first wave launch across 50+ countries; management maintained November 2020 relaunch guidance and expects FY27 sales volume of 6-7 million pens.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.